Episode summary
AI Chipmaker Cerebras Systems Seeks $4.8 Billion in Upsized IPO | Bloomberg Intelligence
Bloomberg Intelligence
· · Hosts: Paul Sweeney, Scarlet Fu · Guests: Carmen Reinicke, Catarina Saraiva, Sam Fazeli
Summary
Cerebras Systems is back in the market with an upsized IPO that could raise nearly $5 billion, reflecting intense investor demand for AI infrastructure. Carmen Reinicke says the company is offering 30 million shares at $150 to $160 each after previously filing and then withdrawing a listing, and the deal is reportedly more than 20 times oversubscribed. The host frames the pricing as unusually aggressive, but the view from the discussion is that AI chip and data center names are still commanding premium valuations because investors want exposure to the buildout.
The conversation on the Federal Reserve focused on Jerome Powell’s legacy as his term as chair ends on May 15. Catarina Saraiva argued that his defining imprint may be both his pandemic-era policy response and the more recent fight to preserve Fed independence from political pressure. She said Powell plans to remain on the Board of Governors until January 31, 2028, but intends to keep a low profile rather than act like a shadow chair.
Sam Fazeli said the FDA is in a period of upheaval, with leadership turnover and staff cuts creating uncertainty for biotech and pharma companies. He described Marty Makary as accessible and open to speeding up drug development, but said the agency needs steadier execution. On hantavirus, he said transmission is not easy, but stressed that public health systems still need to track contacts quickly to prevent further spread.
Key takeaways
- Cerebras Systems is seeking nearly $5 billion in an upsized IPO at $150 to $160 a share, according to Carmen Reinicke.
- The deal is reportedly more than 20 times oversubscribed, showing continued investor appetite for AI infrastructure names.
- Catarina Saraiva said Jerome Powell’s legacy may be defined by pandemic-era policy and the defense of Fed independence from political pressure.
- Saraiva said Powell will remain on the Fed board through January 31, 2028, but plans a low-key role rather than a shadow-chair position.
- Sam Fazeli said the FDA under Marty Makary has brought faster drug-development messaging but also more uncertainty for biotech companies.
- Fazeli said hantavirus is less easily transmitted than COVID, but contact tracing and quarantine remain critical if outbreaks emerge.
Notable quotes
“So, the thing that's interesting here is so it's an artificial artificial intelligence chip maker data center operator”
“the company uh has upsized its initial public offering. So, it's now looking to raise nearly 5 billion”
“there's just so much demand in this category, right? Especially, we we're in this huge buildout. We need data centers”
“I think a lot of people are looking to what's currently going on between the Fed chair and the president as as perhaps really marking, um, Chair Powell's legacy”
“He won't be, you know, we won't be hearing from him a lot. He won't be trying to act as kind of a shadow chair or anything like that”
How the episode opens
Bloomberg Audio Studios. Podcasts, radio, news. You're listening to the Bloomberg Intelligence podcast.
Catch us live weekdays at 10:00 a.m. Eastern on Apple CarPlay and Android Auto with the Bloomberg Business app. Listen on demand wherever you get your podcasts or watch us live on YouTube.
Bloomberg's Carmen Reinicke. Carmen's going to stay with us cuz she wrote a very cool story on yet another monster IPO that is, you guessed it, oversubscribed. Carmen, talk to us about which deal you're looking at here.
Yeah, so we're looking at Cerebras Systems. So, the thing that's interesting here is so it's an artificial artificial intelligence chip maker data center operator. Obviously, all the rage right now, we're seeing so much demand for these kinds of companies.
Uh the company uh has upsized its initial public offering. So, it's now looking to raise nearly 5 billion. Um this is not a few.
So, we had reported previously there were they had you know a different price that they were seeking. And this company also had um applied for an IPO a few months ago and withdrawn that listing. And so, they're they're back to the public market here.
Um but yeah, really significant. It's expected to price later this week. So, we'll be watching for that day as well as well as the launch of
What is what is unusual here is just the IPO price itself. Why is it so high? 135 Initially, it was 115 to 125. You don't see that very often. — Mhm. I know. Well, now we're seeing 150 to 160 each. I mean, I think there's just so much demand in this category, right? Especially, we we're in this huge buildout. We need data centers. There's a chip shortage. So, investors are really like clamoring for more ways to play the AI trade.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- ai chipmaker ipo
- cerebras systems funding
- fed rates powell legacy
- trump fed influence
- biotech sector
Companies and tickers mentioned
- Cerebras Systems
Watch the episode
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Bloomberg Intelligence
-
Instant Reaction: Nvidia CEO Jensen Huang Ousted by Nvidia Board | Bloomberg Intelligence -
Nvidia’s Huang Ousted by Board in Move That Roils AI Economy | Bloomberg Intelligence -
CoreWeave Shares Soar After AI Computing Firm Eases Debt Fears | Bloomberg Intelligence -
Anthropic Targets $1.4 Trillion Valuation in Blockbuster IPO | Bloomberg Intelligence -
Nvidia Probe Into CEO Affair Raises Thorny Questions for AI | Bloomberg Intelligence -
Election 'Blue Wave' & Your Wallet; Navigating AI-Driven Market Volatility | Bloomberg Intelligence
Bloomberg Intelligence, this episode and its artwork belong to Bloomberg. Octagon is not affiliated with the show; this page is an independent summary.
